Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience -- Ignore unavailable to you. Want to Upgrade?

To: John S. Baker who wrote (231)	5/20/1998 10:22:00 AM
From: Jay Lowe	Respond to of 586

Yep ... that was the concern stated several weeks ago directly after the last earnings report. One might presume, given CYPB's funding structure, that acquiring additional capital near the RA filing window would be feasible. The other concern evoked by the last earnings report was that revenues were stated to be down due to the fact that the sales force was concentrating on preparing for the RA launch. This seemed rather like positive spin management since the RA launch is 6 months away. One would expect the sales force to be quite well prepared ... ;-)